Cutaneous T cell lymphoma (CTCL), a heterogeneous group of non-Hodgkin lymphomas is a rare but aggressive cancer that manifests primarily in the skin and remains incurable with current standard therapies. Although there are therapeutic options available for early-stage CTCL, not all patients respond, resulting in refractory CTCL (rCTCL) with limited treatment options and a poor prognosis. The disease is usually slow-growing. The 2 most common types of this form of cancer are mycosis fungoides and Sézary syndrome. Each of the two forms of cutaneous T-cell lymphoma has unique characteristics that distinguish them from other types of non-Hodgkin’s lymphomas.
A presentation at the 62nd Anual American Society of Hematology‘s (ASH) Annual Meeting and Exposition, held virtually December 5 – 8, 2020, demonstrated positive safety and efficacy data from a Phase I/II clinical study of BNZ-1, a pegylated peptide antagonist that binds to the common gamma chain signaling receptor for cytokines interleukin-2 (IL-2), interleukin-9 (IL-9) and interleukin-15 (IL-15), for the treatment of refractory cutaneous T-cell lymphoma (rCTCL).
Read the full article in Onco’Zine